Item Type | Name |
Academic Article
|
The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
|
Academic Article
|
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.
|
Academic Article
|
Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.
|
Academic Article
|
Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.
|
Concept
|
Protein Kinase C
|
Concept
|
Protein Kinase Inhibitors
|
Concept
|
Mitogen-Activated Protein Kinase Kinases
|
Concept
|
Proto-Oncogene Proteins c-akt
|
Concept
|
Mitogen-Activated Protein Kinase 14
|
Academic Article
|
Janus kinase 2: a critical target in chronic myelogenous leukemia.
|
Academic Article
|
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
|
Academic Article
|
A potential role of ruxolitinib in leukemia.
|
Academic Article
|
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.
|
Academic Article
|
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
|
Academic Article
|
New strategies in chronic myeloid leukemia.
|
Academic Article
|
EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
|
Academic Article
|
Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
|
Academic Article
|
Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
|
Academic Article
|
Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications.
|
Academic Article
|
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.
|
Academic Article
|
BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors.
|
Academic Article
|
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy.
|
Academic Article
|
Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.
|
Academic Article
|
Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.
|
Academic Article
|
Advances in the biology and therapy of patients with chronic myeloid leukaemia.
|
Academic Article
|
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.
|
Academic Article
|
Modern treatment programs for adults with acute lymphoblastic leukemia.
|
Academic Article
|
Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.
|
Academic Article
|
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
|
Academic Article
|
Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.
|
Academic Article
|
Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.
|
Academic Article
|
A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
Academic Article
|
Experimental therapeutics for patients with myeloproliferative neoplasias.
|
Academic Article
|
Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia.
|
Academic Article
|
Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia.
|
Academic Article
|
Hematologic malignancies: where do we stand in 2011?
|
Academic Article
|
Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy.
|
Academic Article
|
Dasatinib for the treatment of chronic myeloid leukemia.
|
Academic Article
|
Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
|
Academic Article
|
Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors.
|
Academic Article
|
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
|
Academic Article
|
Evolution of therapies for chronic myelogenous leukemia.
|
Academic Article
|
Randomized, dose-escalation study of the p38a MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome.
|
Academic Article
|
Current practices in the management of chronic myeloid leukemia.
|
Academic Article
|
Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study.
|
Academic Article
|
The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia.
|
Academic Article
|
Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.
|
Academic Article
|
Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.
|
Academic Article
|
Novel approaches in the treatment of systemic mastocytosis.
|
Academic Article
|
Dasatinib.
|
Academic Article
|
The biology of chronic myelogenous leukemia: implications for imatinib therapy.
|
Academic Article
|
Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors.
|
Academic Article
|
The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia.
|
Academic Article
|
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.
|
Academic Article
|
A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry.
|
Academic Article
|
Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia--remarkable activity with room for improvement.
|
Academic Article
|
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
|
Academic Article
|
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.
|
Academic Article
|
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.
|
Academic Article
|
The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
|
Academic Article
|
Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O].
|
Academic Article
|
Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients.
|
Academic Article
|
Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules.
|
Academic Article
|
Introduction: targeting different pathways to prevent tumor cell development.
|
Academic Article
|
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
|
Academic Article
|
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
|
Academic Article
|
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
|
Academic Article
|
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
|
Academic Article
|
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
|
Academic Article
|
Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
|
Academic Article
|
Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
|
Academic Article
|
Monitoring molecular response in chronic myeloid leukemia.
|
Academic Article
|
Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.
|
Academic Article
|
FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?
|
Academic Article
|
Mutant BCR-ABL clones in chronic myeloid leukemia.
|
Academic Article
|
Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors.
|
Academic Article
|
Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.
|
Academic Article
|
Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
|
Academic Article
|
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
|
Academic Article
|
Chronic myeloid leukemia: mechanisms of resistance and treatment.
|
Academic Article
|
Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase.
|
Academic Article
|
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.
|
Academic Article
|
Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
|
Academic Article
|
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.
|
Academic Article
|
EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.
|
Academic Article
|
Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
|
Academic Article
|
Tyrosine kinase inhibitors in acute and chronic leukemias.
|
Academic Article
|
Adherence to BCR-ABL inhibitors: issues for CML therapy.
|
Academic Article
|
Philadelphia-positive acute lymphoblastic leukemia: current treatment options.
|
Academic Article
|
Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment.
|
Academic Article
|
Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
|
Academic Article
|
Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD.
|
Academic Article
|
Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies.
|
Academic Article
|
Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors.
|
Academic Article
|
Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia.
|
Academic Article
|
Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options.
|
Academic Article
|
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.
|
Academic Article
|
Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.
|
Academic Article
|
Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study.
|
Academic Article
|
Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials.
|
Academic Article
|
Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.
|
Academic Article
|
Ruxolitinib for myelofibrosis--an update of its clinical effects.
|
Academic Article
|
Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.
|
Academic Article
|
Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.
|
Academic Article
|
Imatinib mesylate causes hypopigmentation in the skin.
|
Academic Article
|
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.
|
Academic Article
|
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
|
Academic Article
|
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
|
Academic Article
|
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.
|
Academic Article
|
Experimental therapy in myelofibrosis with myeloid metaplasia.
|
Academic Article
|
Important therapeutic targets in chronic myelogenous leukemia.
|
Academic Article
|
Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns.
|
Academic Article
|
Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
|
Academic Article
|
Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity.
|
Academic Article
|
A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia.
|
Academic Article
|
Flying under the radar: the new wave of BCR-ABL inhibitors.
|
Academic Article
|
Tyrosine kinase inhibitors for chronic myelogenous leukemia.
|
Academic Article
|
Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations.
|
Academic Article
|
Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.
|
Academic Article
|
Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies.
|
Academic Article
|
Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
|
Academic Article
|
Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia.
|
Academic Article
|
Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.
|
Academic Article
|
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
|
Academic Article
|
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.
|
Academic Article
|
Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001.
|
Academic Article
|
Imatinib and beyond--exploring the full potential of targeted therapy for CML.
|
Academic Article
|
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.
|
Academic Article
|
Standard management of patients with chronic myeloid leukemia.
|
Academic Article
|
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.
|
Academic Article
|
Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance.
|
Academic Article
|
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
|
Academic Article
|
Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.
|
Academic Article
|
Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects.
|
Academic Article
|
Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy?
|
Academic Article
|
Third-generation tyrosine kinase inhibitors and beyond.
|
Academic Article
|
Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors.
|
Academic Article
|
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.
|
Academic Article
|
Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.
|
Academic Article
|
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.
|
Academic Article
|
New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.
|
Academic Article
|
Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
|
Academic Article
|
Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells.
|
Academic Article
|
The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.
|
Academic Article
|
The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?
|
Academic Article
|
Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes.
|
Academic Article
|
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.
|
Academic Article
|
Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy.
|
Academic Article
|
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
|
Academic Article
|
Regulation of HIF-1a signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment.
|
Academic Article
|
Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.
|
Academic Article
|
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.
|
Academic Article
|
Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.
|
Academic Article
|
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
|
Academic Article
|
Chronic myeloid leukemia: overview of new agents and comparative analysis.
|
Academic Article
|
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.
|
Academic Article
|
Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.
|
Academic Article
|
Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months.
|
Academic Article
|
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.
|
Academic Article
|
Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies.
|
Academic Article
|
A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.
|
Academic Article
|
Ponatinib in Philadelphia chromosome-positive leukemias.
|
Academic Article
|
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
|
Academic Article
|
Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.
|
Academic Article
|
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
|
Academic Article
|
Activation of class I HLA expression by TNF-alpha and gamma-interferon is mediated through protein kinase C-dependent pathway in CML cell lines.
|
Academic Article
|
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
|
Academic Article
|
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
|
Academic Article
|
Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.
|
Academic Article
|
Current and emerging treatment options in chronic myeloid leukemia.
|
Academic Article
|
Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406.
|
Academic Article
|
Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias.
|
Academic Article
|
Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
|
Academic Article
|
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
|
Academic Article
|
First-line therapy for chronic myeloid leukemia: Past, present, and future.
|
Academic Article
|
Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.
|
Academic Article
|
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
|
Academic Article
|
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
|
Academic Article
|
New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia.
|
Academic Article
|
Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia.
|
Academic Article
|
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.
|
Academic Article
|
Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib.
|
Academic Article
|
Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: long-term implications.
|
Academic Article
|
Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
Academic Article
|
The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm.
|
Academic Article
|
Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.
|
Academic Article
|
Molecular resistance: an early indicator for treatment change?
|
Academic Article
|
Bosutinib for the treatment of chronic myeloid leukemia in chronic phase.
|
Academic Article
|
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.
|
Academic Article
|
The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure.
|
Academic Article
|
The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.
|
Academic Article
|
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
|
Academic Article
|
BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia.
|
Academic Article
|
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
|
Academic Article
|
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
|
Academic Article
|
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
|
Academic Article
|
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.
|
Academic Article
|
Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia.
|
Academic Article
|
Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.
|
Academic Article
|
Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?
|
Academic Article
|
Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure.
|
Academic Article
|
Suboptimal responses in chronic myeloid leukemia: implications and management strategies.
|
Academic Article
|
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.
|
Academic Article
|
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
|
Academic Article
|
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
|
Academic Article
|
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
|
Academic Article
|
Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience.
|
Academic Article
|
Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.
|
Academic Article
|
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.
|
Academic Article
|
Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy.
|
Academic Article
|
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study.
|
Academic Article
|
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
|
Academic Article
|
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
|
Academic Article
|
Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia.
|
Academic Article
|
Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia.
|
Academic Article
|
Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.
|
Academic Article
|
A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.
|
Academic Article
|
A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.
|
Academic Article
|
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.
|
Academic Article
|
Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.
|
Academic Article
|
Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.
|
Academic Article
|
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
|
Academic Article
|
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
|
Academic Article
|
The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
Academic Article
|
Secondary mutations as mediators of resistance to targeted therapy in leukemia.
|
Academic Article
|
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.
|
Academic Article
|
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.
|
Academic Article
|
Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.
|
Academic Article
|
Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1.
|
Academic Article
|
Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study.
|
Academic Article
|
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
|
Academic Article
|
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.
|
Academic Article
|
Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
|
Academic Article
|
Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors.
|
Academic Article
|
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.
|
Academic Article
|
Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor.
|
Academic Article
|
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
|
Academic Article
|
Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015.
|
Academic Article
|
Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.
|
Academic Article
|
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
|
Academic Article
|
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.
|
Academic Article
|
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.
|
Academic Article
|
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies
|
Academic Article
|
Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
|
Academic Article
|
Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.
|
Academic Article
|
Acute myeloid leukemia: advancing clinical trials and promising therapeutics.
|
Academic Article
|
Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib.
|
Academic Article
|
Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.
|
Academic Article
|
Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
|
Academic Article
|
Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
|
Academic Article
|
Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
|
Academic Article
|
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
|
Academic Article
|
Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.
|
Academic Article
|
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
|
Academic Article
|
Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis.
|
Academic Article
|
MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells.
|
Academic Article
|
Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors.
|
Academic Article
|
Adult Acute Lymphoblastic Leukemia.
|
Academic Article
|
Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib.
|
Academic Article
|
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.
|
Academic Article
|
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.
|
Academic Article
|
Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship.
|
Academic Article
|
Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor.
|
Academic Article
|
A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia.
|
Academic Article
|
Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
|
Academic Article
|
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
|
Academic Article
|
Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias.
|
Academic Article
|
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia.
|
Academic Article
|
Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting.
|
Academic Article
|
Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?
|
Academic Article
|
Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors.
|
Academic Article
|
Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives.
|
Academic Article
|
Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.
|
Academic Article
|
Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase.
|
Academic Article
|
Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring.
|
Academic Article
|
Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia.
|
Academic Article
|
Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib.
|
Academic Article
|
A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors.
|
Academic Article
|
Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers.
|
Academic Article
|
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.
|
Academic Article
|
Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.
|
Academic Article
|
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience.
|
Academic Article
|
Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
|
Academic Article
|
Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
|
Academic Article
|
Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia.
|
Academic Article
|
Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy.
|
Academic Article
|
Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
|
Academic Article
|
Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series.
|
Academic Article
|
Long-term follow-up of lower dose dasatinib (50?mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
|
Academic Article
|
Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.
|
Academic Article
|
Treatment-free remission in chronic myeloid leukemia.
|
Academic Article
|
Long-term results of a phase 2 trial of nilotinib 400?mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia.
|
Academic Article
|
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
|
Academic Article
|
Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
|
Academic Article
|
Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia.
|
Academic Article
|
Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL.
|
Academic Article
|
Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.
|
Academic Article
|
Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL.
|
Academic Article
|
Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology.
|
Academic Article
|
Chronic myeloid leukemia: sequencing of TKI therapies.
|
Academic Article
|
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
|
Academic Article
|
NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017.
|
Academic Article
|
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.
|
Academic Article
|
Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
|
Academic Article
|
Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience.
|
Academic Article
|
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.
|
Academic Article
|
Acute myeloid leukemia: current progress and future directions.
|
Academic Article
|
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors.
|
Academic Article
|
High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells.
|
Academic Article
|
Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors.
|
Academic Article
|
Impact of frontline treatment approach on outcomes of myeloid blast phase CML.
|
Academic Article
|
Current Approaches to Philadelphia Chromosome-Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant.
|
Academic Article
|
Ibrutinib induces durable remissions in treatment-na?ve patients with CLL and 17p deletion and/or TP53 mutations.
|
Academic Article
|
SOHO State of the Art Updates & Next Questions: Intensive and Non-Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
|
Academic Article
|
The cure of leukemia through the optimist's prism.
|
Academic Article
|
Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia.
|
Academic Article
|
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors.
|
Academic Article
|
Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML.
|
Academic Article
|
TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis.
|
Academic Article
|
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
|
Academic Article
|
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee.
|
Academic Article
|
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
|
Academic Article
|
Real-life incidence of thrombotic events in leukemia patients treated with ponatinib.
|
Academic Article
|
Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review.
|
Academic Article
|
Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
|
Academic Article
|
Low-dose dasatinib 50?mg/day versus standard-dose dasatinib 100?mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis.
|
Academic Article
|
The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA.
|
Academic Article
|
Chronic myeloid leukemia without major molecular response after 2?years of treatment with tyrosine kinase inhibitor.
|
Academic Article
|
The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors.
|
Academic Article
|
Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia.
|
Academic Article
|
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis.
|
Academic Article
|
The emerging use of chemotherapy-free regimens in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
Academic Article
|
Association between bariatric surgery and outcomes in chronic myeloid leukemia.
|
Academic Article
|
Management of chronic myeloid leukemia in 2023 - common ground and common sense.
|
Academic Article
|
Classification of accelerated phase chronic myeloid leukemia in the era of the BCR::ABL1 tyrosine kinase inhibitors: A work in progress.
|
Academic Article
|
Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results.
|
Academic Article
|
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.
|
Academic Article
|
Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019.
|
Academic Article
|
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
|
Academic Article
|
Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors.
|